Pharmaceutical - MedImmune

Filter

Current filters:

MedImmune

Popular Filters

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

Positive top-line results for MedImmune RA and lupus treatments

Positive top-line results for MedImmune RA and lupus treatments

13-05-2014

Anglo-Swedish drug major AstraZeneca has announced that two key molecules in its global biologics R&D…

Anti-Arthritics/RheumaticsAstraZenecaBahija JallalHealthHealth Medical PharmaMajorMedicineMedImmunePharmaceuticalResearchUK

Medimmune announces research deals with University of Cambridge and University of Texas

Medimmune announces research deals with University of Cambridge and University of Texas

18-03-2014

USA-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

MedImmuneOncologyPharmaceuticalResearchUKUSA

Immunologist Yong-Jun Liu named head of research at MedImmune

Immunologist Yong-Jun Liu named head of research at MedImmune

20-11-2013

US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca…

BoardroomImmunologicalsMedImmuneNorth AmericaPharmaceuticalUSA

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances Medimmune’s benralizumab to Phase III in severe asthma

30-10-2013

AstraZeneca has started the Phase III Windward program for benralizumab, a potential treatment for severe…

AstraZenecaEuropeKyowa Hakko KirinMedImmunePharmaceuticalResearchRespiratory and Pulmonary

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

15-10-2013

AstraZeneca revealed this morning that its biologics subsidiary MedImmune has acquired Spirogen, a privately-held…

ADC TherapeuticsAstraZenecaMedImmuneMergers & AcquisitionsOncologyPharmaceuticalSpirogen

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

AstraZeneca plans to move three cancer drug candidates into Ph III

16-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning (May 16) announced that it will be moving…

AstraZenecaBiotechnologyMedImmunemoxetumomab pasudotoxolaparibOncologyPharmaceuticalResearchselumetinib

Evotec acquires Cell Culture Service GmbH; expands deal with AstraZeneca

07-01-2013

German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS),…

AstraZenecaBiotechnologyCell Culture Service GmbHDiabetesEvotecLicensingMedImmuneMergers & AcquisitionsPharmaceutical

Further $100 million committed to AstraZeneca’s MedImmune Ventures

29-11-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed yesterday that it has committed an additional…

AstraZenecaFinancialMedImmuneMergers & AcquisitionsPharmaceutical

AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy

02-11-2011

USA-based AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics…

AgonOxAstraZenecaBiotechnologyLicensingMedImmuneOncologyPharmaceuticalResearch

AstraZeneca unit in-licenses Pfizer drug candidate tremelimumab

04-10-2011

Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) US biologics subsidiary MedImmune has in-licensed…

AstraZenecaLicensingMedImmuneOncologyPfizerPharmaceutical

Back to top